bcl-xL antisense oligodeoxynucleotides

Bcl-xL antisense oligodeoxynucleotides are synthetic short single-stranded DNA molecules designed to hybridize specifically to the mRNA of Bcl-xL (BCL2L1), an anti-apoptotic protein of the Bcl-2 family, thereby inhibiting its translation and reducing protein expression. Mechanistically, these antisense oligonucleotides bind to the complementary Bcl-xL mRNA, recruiting RNase H1 that cleaves the mRNA and results in its degradation, thus lowering Bcl-xL protein levels[4][7][9][12][15]. Reducing Bcl-xL, which is often overexpressed in various cancers and confers resistance to apoptosis, sensitizes cancer cells to radiotherapy or chemotherapy and induces apoptosis[1][4][7][20]. Bcl-xL antisense oligonucleotides have been studied mainly as experimental molecular therapeutics for treatment-resistant or aggressive cancers including colon cancer and bladder cancer.

Other names

bcl-xL ASOBcl-xL antisense ODNBcl-xL antisense oligonucleotide